JP6836756B2 - How to predict the composition ratio in the oral bacterial flora - Google Patents

How to predict the composition ratio in the oral bacterial flora Download PDF

Info

Publication number
JP6836756B2
JP6836756B2 JP2017181000A JP2017181000A JP6836756B2 JP 6836756 B2 JP6836756 B2 JP 6836756B2 JP 2017181000 A JP2017181000 A JP 2017181000A JP 2017181000 A JP2017181000 A JP 2017181000A JP 6836756 B2 JP6836756 B2 JP 6836756B2
Authority
JP
Japan
Prior art keywords
ratio
phylum bacteria
oral
flora
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017181000A
Other languages
Japanese (ja)
Other versions
JP2019054752A (en
Inventor
光博 岡野
光博 岡野
厚司 湯田
厚司 湯田
Original Assignee
光博 岡野
光博 岡野
医療法人Ayns
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 光博 岡野, 光博 岡野, 医療法人Ayns filed Critical 光博 岡野
Priority to JP2017181000A priority Critical patent/JP6836756B2/en
Publication of JP2019054752A publication Critical patent/JP2019054752A/en
Application granted granted Critical
Publication of JP6836756B2 publication Critical patent/JP6836756B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Description

本発明は口腔細菌叢の構成叢比を簡易に予測する方法に関するものである。 The present invention relates to a method for easily predicting the compositional plexus ratio of the oral bacterial flora.

口腔細菌叢(フローラ)の主要な構成叢として、Bacteroidetes門細菌、Proteobacteria門細菌及びFirmicutes門細菌がある。口腔細菌叢の構成異常は歯周病などの口腔疾患のみならず、炎症性腸疾患などの重篤な全身疾患にも関与すると言われており(非特許文献1)、例えば炎症性腸疾患では口腔細菌叢のBacteroidetes門細菌が増加し、Proteobacteria門細菌が減少することが報告されており(非特許文献2)、癌において同様の報告がされている(非特許文献3)。さらに発明者らは、Bacteroidetes門細菌やProteobacteria門細菌の含有率が、アレルギー性鼻炎の治療方法である舌下免疫療法の治療効果に関与することを見いだしている(図1)。 The major constituents of the oral flora are Bacteroidetes, Proteobacteria and Firmicutes. It is said that abnormal composition of the oral bacterial flora is involved not only in oral diseases such as periodontal disease but also in serious systemic diseases such as inflammatory bowel disease (Non-Patent Document 1). It has been reported that Bacteria phylum bacteria in the oral flora increase and Proteobacteria phylum bacteria decrease (Non-Patent Document 2), and similar reports have been made in cancer (Non-Patent Document 3). Furthermore, the inventors have found that the content of Bacteroidetes and Proteobacteria is involved in the therapeutic effect of sublingual immunotherapy, which is a method for treating allergic rhinitis (Fig. 1).

一方、口腔などの菌叢構造を網羅的に解析する手法として、現在ではメタ16sRNA解析とメタゲノム解析が主流であるが、これらの方法では、詳細な菌叢を検知できるが、解析に必要な時間と費用の面で課題がある。すなわち、1検体当たりのメタ16sRNA解析には高額の費用が必要であり、メタゲノム解析ではさらに高額となる。また、医療機関内で解析を行うことが困難であるため、医療機関で唾液を採取し、専門検査機関に唾液を送付し、口腔細菌叢(フローラ)解析を依頼してから解析結果を得るまでに2月以上を要することもある。 On the other hand, meta 16sRNA analysis and metagenomic analysis are currently the mainstream methods for comprehensively analyzing the flora structure of the oral cavity, etc., but these methods can detect detailed flora, but the time required for analysis. And there is a problem in terms of cost. That is, meta 16sRNA analysis per sample requires a high cost, and metagenome analysis is even more expensive. In addition, since it is difficult to perform analysis within a medical institution, saliva is collected at the medical institution, sent to a specialized laboratory, and the oral bacterial flora (flora) analysis is requested until the analysis result is obtained. It may take more than two months.

Wade WG. The oral microbiome in health and disease. Pharmacological Research 69: 137-143, 2013Wade WG. The oral microbiome in health and disease. Pharmacological Research 69: 137-143, 2013 Said HS, et al. Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. DNA Research 21: 15-25, 2014.Said HS, et al. Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. DNA Research 21: 15-25, 2014. Le Bars P, et al. The oral cavity microbiota: between health, oral disease, and cancers of the aerodigestive tract. Canadian Journal of Microbiology 63: 475-492, 2017.Le Bars P, et al. The oral cavity microbiota: between health, oral disease, and cancers of the aerodigestive tract. Canadian Journal of Microbiology 63: 475-492, 2017.

これらのことから、簡便で医療機関内の施設で解析でき、短期間、安価な口腔細菌叢の解析方法が求められている。 From these facts, there is a demand for an inexpensive method for analyzing oral bacterial flora in a short period of time, which can be easily analyzed at a facility in a medical institution.

本発明者らは、THP−1細胞の培養液に被験者から採取した唾液を加え、更に培養した後、培養液中のインターロイキン−10(IL−10)の量を測定することによりBacteroidetes門細菌のProteobacteria門細菌に対する量比、口腔細菌叢中のBacteroidetes門細菌の含有比率(以下、単に比率ということもある)および口腔細菌叢中のProteobacteria門細菌の含有比率を予測することができることを見出し、本発明を完成した。 The present inventors added saliva collected from a subject to the culture solution of THP-1 cells, further cultured the cells, and then measured the amount of interleukin-10 (IL-10) in the culture solution to measure the amount of Bacteroidetes phylum bacteria. We found that it is possible to predict the abundance ratio of Proteobacteria to Proteobacteria, the content ratio of Bacteroidetes phylum bacteria in the oral flora (hereinafter, also referred to simply as the ratio), and the content ratio of Proteobacteria in the oral flora. The present invention has been completed.

すなわち、本発明は以下の特徴を有する。
[1]単球細胞培養液に唾液を加え、さらに培養し、培養液中のインターロイキン−10の量を測定する工程を含む、口腔細菌叢中の構成叢比の予測方法、
[2]単球細胞がヒト単球細胞である[1]記載の方法、
[3]ヒト単球細胞がTHP−1細胞である[2]記載の方法、
[4]構成叢比が、口腔細菌叢中のBacteroidetes門細菌の含有比率である[1]記載の方法、
[5]構成叢比が、口腔細菌叢中のProteobacteria門細菌の含有比率である[1]記載の方法、
[6]構成叢比が、Bacteroidetes門細菌の含有比率のProteobacteria門細菌の含有比率に対する量比である[1]記載の方法、および
[7]口腔細菌叢中の構成叢比を予測するためのインターロイキン−10量測定キット。
That is, the present invention has the following features.
[1] A method for predicting the composition ratio in the oral bacterial flora, which comprises a step of adding saliva to a monocyte cell culture medium, further culturing the culture solution, and measuring the amount of interleukin-10 in the culture medium.
[2] The method according to [1], wherein the monocyte cell is a human monocyte cell.
[3] The method according to [2], wherein the human monocyte cell is a THP-1 cell.
[4] The method according to [1], wherein the composition plexus ratio is the content ratio of Bacteroidetes phylum bacteria in the oral plexus.
[5] The method according to [1], wherein the constituent plexus ratio is the content ratio of Proteobacteria phylum bacteria in the oral bacterial flora.
[6] The method according to [1], wherein the compositional flora ratio is an amount ratio of the content ratio of Bacteroidetes phylum bacteria to the content ratio of Proteobacteria phylum bacteria, and [7] for predicting the compositional flora ratio in the oral bacterial flora. Interleukin-10 quantity measurement kit.

本発明によれば簡便に口腔細菌叢の予測をすることができる。 According to the present invention, the oral bacterial flora can be easily predicted.

舌下免疫療法の有効性と口腔細菌叢の構成叢比との関係を示す。すなわち、舌下免疫療法が著効した患者(Visual anaalogue scale(VAS)スコアが0)が、無効であった患者(VASスコアが95以上)の患者に比べBacteroidetes門細菌の比率が高く、Proteobacteria門細菌の比率が低いことを示す。図中、Pは有意確率(Mann−Whitney test)を示す。The relationship between the effectiveness of sublingual immunotherapy and the composition ratio of the oral bacterial flora is shown. That is, patients who responded significantly to sublingual immunotherapy (visual analog scale (VAS) score 0) had a higher proportion of Bacteroidetes phylum bacteria than patients who did not respond (VAS score 95 or higher), and the Proteobacteria phylum Indicates a low proportion of bacteria. In the figure, P indicates a significant probability (Mann-Whitney test). 培養液中のIL−10濃度と口腔細菌叢中のBacteroidetes門細菌含有比率の相関を示す。図中、Rは相関係数を、Pは有意確率(Mann−Whitney test)を示す。The correlation between the IL-10 concentration in the culture medium and the Bacteroidetes phylum bacteria content ratio in the oral flora is shown. In the figure, R indicates the correlation coefficient, and P indicates the significance probability (Mann-Whitney test). 培養液中のIL−10濃度と口腔細菌叢中のProteobacteria門細菌含有比率の相関を示す。図中、Rは相関係数を、Pは有意確率(Mann−Whitney test)を示す。The correlation between the IL-10 concentration in the culture medium and the Proteobacteria content ratio in the oral flora is shown. In the figure, R indicates the correlation coefficient, and P indicates the significance probability (Mann-Whitney test). 培養液中のIL−10濃度と、口腔細菌叢中のBacteroidetes門細菌のProteobacteria門細菌に対する量比(Bacteroidetes門細菌の比率/Proteobacteria門細菌の比率)を示す。図中、Rは相関係数を、Pは有意確率(Mann−Whitney test)を示す。The IL-10 concentration in the culture solution and the amount ratio of Bacteroidetes phylum bacteria to Proteobacteria phylum bacteria in the oral flora (ratio of Bacteroidetes phylum bacteria / ratio of Proteobacteria phylum bacteria) are shown. In the figure, R indicates the correlation coefficient, and P indicates the significance probability (Mann-Whitney test).

本発明に用いる単球細胞は、単球細胞であれば適宜用いることができるが、ヒト単球細胞が好ましく、THP−1細胞がより好ましい。THP−1細胞は商業的に入手可能であり、例えば、コスモバイオ株式会社から入手できる。 The monocyte cell used in the present invention can be appropriately used as long as it is a monocyte cell, but human monocyte cell is preferable, and THP-1 cell is more preferable. THP-1 cells are commercially available, for example from Cosmo Bio Co., Ltd.

THP−1細胞の培養は、一般にTHP−1細胞の培養方法として用いられている方法であれば適宜用いることができるが、RPMI1640などの培地を10%のウシ胎児血清(Fetal calf serum: FCS)存在下、5%CO(二酸化炭素)、37℃の環境において培養することが好ましい。培養中、培地は2〜3日に一度交換し、細胞数を2〜8x10個/mLに維持し、必要に応じて継代培養することが好ましい。 Culturing of THP-1 cells can be appropriately used as long as it is a method generally used as a method for culturing THP-1 cells, but a medium such as RPMI1640 is used as 10% fetal bovine serum (FCS). In the presence, it is preferable to culture in an environment of 5% CO 2 (carbon dioxide) and 37 ° C. During culturing, it is preferable to change the medium once every 2 to 3 days, maintain the number of cells at 2 to 8x10 5 cells / mL, and subculture if necessary.

単球細胞を上記条件下で培養し、被験者から採取した唾液を培養液に加える。唾液の採取方法は適宜選択することができるが、Saliva collecetion aid(Salimetrics社)または類似の器具を用いることができる。唾液は希釈せずに用いることもできるが、適宜希釈して用いることもできる。希釈は通常用いられる緩衝液を適宜用いて行うことができるが、PBS(リン酸緩衝生理食塩水)を用いることが好ましい。また、唾液は採取後冷蔵保存したのちに用いることもできるが、採取直後に用いることが好ましい。 Monocyte cells are cultured under the above conditions, and saliva collected from the subject is added to the culture medium. The method of collecting saliva can be appropriately selected, but Saliva collection aid (Salimetrics) or a similar device can be used. Saliva can be used without being diluted, but it can also be used after being appropriately diluted. Dilution can be carried out by appropriately using a commonly used buffer solution, but it is preferable to use PBS (phosphate buffered saline). In addition, saliva can be used after collection and refrigerated, but it is preferable to use it immediately after collection.

唾液はTHP−1細胞培養液0.5mLあたり0.05μL〜50μL(希釈なしの場合)加えることができ、好ましくは5μLである。 Saliva can be added from 0.05 μL to 50 μL (without dilution) per 0.5 mL of THP-1 cell culture, preferably 5 μL.

唾液を加えたのち、単球細胞(例えば、THP−1細胞)を更に培養する。単球細胞(例えば、THP−1細胞)は上記培養方法と同様に行うことができる。培養時間は、好ましくは12〜48時間、より好ましくは12〜36時間、さらに好ましくは24時間である。 After adding saliva, monocyte cells (eg, THP-1 cells) are further cultured. Monocyte cells (for example, THP-1 cells) can be subjected to the same culture method as described above. The culturing time is preferably 12 to 48 hours, more preferably 12 to 36 hours, and even more preferably 24 hours.

培養終了後、培養上清に含まれるIL−10量を測定する。IL−10量の測定は自体公知の方法を用いることができ、特に限定されない。ウエスタンブロット法、RIA法、ELISA法などを用いることができるが、ELISA法が好ましい。ELISA法は、IL−10量を測定できるものであればよいが、抗ヒトIL−10モノクローナル抗体(キャプチャー用抗体)でコートしたプレートにIL−10を含む培養液を添加し、さらに抗IL−10モノクローナル抗体(検出用抗体)を添加し、当該検出抗体量を測定するサンドイッチELISA法が好ましい。検出用抗体は標識することができ、標識方法としてビオチン化標識を選択した場合、アビジンと結合させた酵素(horseradish peroxidaseなど)などを用い、酵素活性を測定することによりIL−10量を測定することができる。 After completion of the culture, the amount of IL-10 contained in the culture supernatant is measured. The measurement of the amount of IL-10 can be performed by a method known per se, and is not particularly limited. Western blotting, RIA method, ELISA method and the like can be used, but ELISA method is preferable. The ELISA method may be any as long as it can measure the amount of IL-10, but a culture solution containing IL-10 is added to a plate coated with an anti-human IL-10 monoclonal antibody (capture antibody), and further anti-IL- A sandwich ELISA method in which 10 monoclonal antibodies (detection antibodies) are added and the amount of the detected antibodies is measured is preferable. The detection antibody can be labeled, and when biotinylated labeling is selected as the labeling method, the amount of IL-10 is measured by measuring the enzyme activity using an enzyme bound to avidin (such as horseradish peroxidase). be able to.

口腔細菌叢中の構成叢比を予測するためのインターロイキン−10量測定キットは、例えばサンドイッチELISA法によりIL−10量を測定するものが挙げられ、キットには、例えば、抗ヒトIL−10モノクローナル抗体などのキャプチャー用抗体、ビオチン化された抗IL−10モノクローナル抗体などの検出用抗体、アビジンと結合させた酵素(horseradish peroxidaseなど)、酵素活性測定用試薬、検量線作成のためのスタンダードとして用いるためのヒトIL−10、各種緩衝液、96穴プレート、取扱説明書などが含まれる。 Examples of the interleukin-10 amount measurement kit for predicting the composition ratio in the oral bacterial flora include those for measuring the IL-10 amount by the sandwich ELISA method, and the kit includes, for example, anti-human IL-10. As a capture antibody such as a monoclonal antibody, a detection antibody such as a biotinylated anti-IL-10 monoclonal antibody, an enzyme bound to avidin (such as horseradish peroxydase), a reagent for measuring enzyme activity, and a standard for preparing a calibration line. Includes human IL-10 for use, various buffers, 96-well plates, instruction manuals and the like.

培養液中のIL−10の測定値が、例えば、30pg/mL以上のとき、口腔細菌叢中のBacteroidetes門細菌含有比率が30%以上と予測することができる(感度89%、特異度83%)。培養液中のIL−10の測定値が、例えば、30pg/mL以上のとき、口腔細菌叢中のProteobacteria門細菌含有比率が20%未満と予測することができる(感度83%、特異度89%)。また、培養液中のIL−10の測定値が、例えば、85pg/mL以上のとき、口腔細菌叢中のBacteroidetes門細菌のProteobacteria門細菌に対する量比(Bacteroidetes門細菌の比率/Proteobacteria門細菌の比率)が1.7以上と予測することができる(感度100%、特異度88%)。 When the measured value of IL-10 in the culture solution is, for example, 30 pg / mL or more, it can be predicted that the content ratio of Bacteroidetes phylum bacteria in the oral flora is 30% or more (sensitivity 89%, specificity 83%). ). When the measured value of IL-10 in the culture medium is, for example, 30 pg / mL or more, it can be predicted that the Proteobacteria content ratio in the oral flora is less than 20% (sensitivity 83%, specificity 89%). ). Further, when the measured value of IL-10 in the culture medium is, for example, 85 pg / mL or more, the amount ratio of Bacteroidetes phylum bacteria to Proteobacteria phylum bacteria in the oral flora (ratio of Bacteroidetes phylum bacteria / ratio of Proteobacteria phylum bacteria). ) Can be predicted to be 1.7 or more (sensitivity 100%, specificity 88%).

培養液中のIL−10濃度の高いほど口腔細菌叢中のBacteroidetes門細菌のProteobacteria門細菌に対する量比(Bacteroidetes門細菌の比率/Proteobacteria門細菌の比率)が大きく、炎症性腸疾患の罹患リスクが高い(あるいは罹患している)と予測することができる。 The higher the IL-10 concentration in the culture solution, the higher the amount ratio of Bacteroidetes phylum bacteria to Proteobacteria phylum bacteria in the oral flora (ratio of Bacteroidetes phylum bacteria / ratio of Proteobacteria phylum bacteria), and the risk of developing inflammatory bowel disease. It can be predicted to be high (or affected).

培養液中のIL−10濃度の高いほど口腔細菌叢中のBacteroidetes門細菌のProteobacteria門細菌に対する量比(Bacteroidetes門細菌の比率/Proteobacteria門細菌の比率)が大きく、舌下免疫療法の有効性が高いと予測することができる。 The higher the IL-10 concentration in the culture medium, the greater the amount ratio of Bacteroidetes phylum bacteria to Proteobacteria phylum bacteria in the oral flora (ratio of Bacteroidetes phylum bacteria / ratio of Proteobacteria phylum bacteria), and the effectiveness of sublingual immunotherapy is high. It can be predicted to be high.

メタ16sRNA解析は、Archaea predominate among ammonia-oxidizing prokaryotes in soils. Leininger, S. et al. Nature. 2006 442, 806-809.、Pyrosequencing enumerates and contrasts soil microbial diversity. Roesch, L.F. et al. ISME J. 2007 1, 283-290.、A core gut microbiome in obese and lean twins. Turnbaugh, P.J. et al. Nature. 2009 457, 480-484.、Human gut microbiota in obesity and after gastric bypass. Zhang, H. et al. Proc. Natl. Acad. Sci. U.S.A. 2009 106, 2365-2370.等の文献を参考にして行うことができる。 Meta 16s RNA analysis was performed on Archaea predominate among ammonia-oxidizing prokaryotes in soils. Leininger, S. et al. Nature. 2006 442, 806-809., Pyrosequencing enumerates and contrasts soil microbial diversity. Roesch, LF et al. ISME J. 2007 1, 283-290., A core gut microbiome in obese and lean twins. Turnbaugh, PJ et al. Nature. 2009 457, 480-484., Human gut microbiota in obesity and after gastric bypass. Zhang, H. et al. This can be done by referring to documents such as Proc. Natl. Acad. Sci. USA 2009 106, 2365-2370.

[実施例1]
15名の被験者から唾液を採取し、冷蔵保存し、PBSで唾液が1%になるように希釈した。10%のウシ胎児血清(Fetal calf serum: FCS)を加えたRPMI1640培地中で、37℃、5%COにおいて培養液中の濃度が0.8×10個/mLになるように培養したTHP−1細胞培養液500μLに、唾液5μLを添加した。さらに37℃、5%COにおいて24時間培養したのち培養上清を回収し、上清中のIL−10量をELISA法により測定した。ELISAは、BD Biosciences社のHuman IL−10 Elisa Set(カタログ番号:555157)を用い、添付されたTechnical Data Sheetに記載された方法で行った。
[Example 1]
Saliva was collected from 15 subjects, stored refrigerated, and diluted with PBS to 1% saliva. The cells were cultured in RPMI1640 medium containing 10% fetal bovine serum (FCS) at 37 ° C. and 5% CO 2 so that the concentration in the culture medium was 0.8 × 10 6 cells / mL. To 500 μL of THP-1 cell culture medium, 5 μL of saliva was added. Further, after culturing at 37 ° C. and 5% CO 2 for 24 hours, the culture supernatant was collected, and the amount of IL-10 in the supernatant was measured by the ELISA method. ELISA was performed using Human IL-10 Elisa Set (catalog number: 555157) from BD Biosciences, as described in the attached Technical Data Sheet.

被験者から採取した同一の唾液サンプル中に含まれるBacteroidetes門細菌、Proteobacteria門細菌及びFirmicutes門細菌の量比をメタ16sRNA解析により算出した(株式会社マクロジェン・ジャパン)。 The amount ratio of Bacteroidetes phylum, Proteobacteria phylum and Firmicutes phylum bacteria contained in the same saliva sample collected from the subject was calculated by meta 16sRNA analysis (Macrogen Japan Co., Ltd.).

被験者ごとのIL−10濃度およびメタ16sRNA解析結果(Bacteroidetes門細菌、Proteobacteria門細菌およびFirmicutes門細菌の比率)を表1に示す。 Table 1 shows the IL-10 concentration and the meta 16sRNA analysis results (ratio of Bacteroidetes phylum, Proteobacteria phylum and Firmicutes phylum bacteria) for each subject.

Figure 0006836756
Figure 0006836756

培養液中のIL−10濃度とBacteroidetes門細菌比率が正の相関(R=0.814)を示し(図2)、培養液中のIL−10濃度とProteobacteria門細菌が負の相関(R=−0.873)を示した(図3)。また、同様に培養液中のIL−10濃度と、Bacteroidetes門細菌とProteobacteria門細菌との量比(Bacteroidetes門細菌の比率/Proteobacteria門細菌の比率)が正の相関(R=0.896)を示すことが明らかとなった(図4)。相関係数はGraphPad Prismを用いてスピアマンの順位相関係数を算出した。 The IL-10 concentration in the culture medium and the ratio of Bacteroidetes phylum bacteria showed a positive correlation (R = 0.814) (Fig. 2), and the IL-10 concentration in the culture medium and the Proteobacteria phylum bacteria had a negative correlation (R = 0.814). −0.873) was shown (Fig. 3). Similarly, the IL-10 concentration in the culture solution and the amount ratio of Bacteroidetes phylum bacteria to Proteobacteria phylum bacteria (ratio of Bacteroidetes phylum bacteria / ratio of Proteobacteria phylum bacteria) have a positive correlation (R = 0.896). It became clear to show (Fig. 4). As the correlation coefficient, Spearman's rank correlation coefficient was calculated using GraphPad Prism.

以上の事から、IL−10量を測定することにより口腔細菌叢の構成比を予測できることが明らかとなった。 From the above, it was clarified that the composition ratio of the oral bacterial flora can be predicted by measuring the amount of IL-10.

本発明によって、安価かつ短時間で口腔内細菌の構成(主要細菌叢)を予測することができる。例えば本検査法にてIL−10量を測定することにより、Bacteroidetes門細菌の優位性(Bacteroidetes門細菌比率/Proteobacteria門細菌比率が大きい)が確認できれば、炎症性腸疾患のリスクを示すことができる。このことから、本発明が口腔細菌叢の関与する疾患の早期発見や早期治療、舌下免疫療法の治療効果予測などに有用である可能性が示される。 According to the present invention, the composition of oral bacteria (major bacterial flora) can be predicted inexpensively and in a short time. For example, if the superiority of Bacteroidetes phylum bacteria (the ratio of Bacteroidetes phylum bacteria / Proteobacteria phylum bacteria is large) can be confirmed by measuring the amount of IL-10 by this test method, the risk of inflammatory bowel disease can be shown. .. This suggests that the present invention may be useful for early detection and treatment of diseases associated with the oral flora, prediction of therapeutic effect of sublingual immunotherapy, and the like.

Claims (5)

単球細胞培養液に唾液を加え、さらに培養し、培養液中のインターロイキン−10の量を測定することによる、
・口腔細菌叢中のBacteroidetes門細菌の含有比率、
・口腔細菌叢中のProteobacteria門細菌の含有比率、または
・Bacteroidetes門細菌の含有比率のProteobacteria門細菌の含有比率に対する量比
のいずれかの口腔細菌叢中の構成叢比の予測方法。
By adding saliva to the monocyte cell culture medium, further culturing, and measuring the amount of interleukin-10 in the culture medium.
・ Content ratio of Bacteroidetes phylum bacteria in the oral flora,
-Content ratio of Proteobacteria phylum bacteria in the oral flora, or
-Amount ratio of the content ratio of Bacteroidetes phylum bacteria to the content ratio of Proteobacteria phylum bacteria
A method for predicting the compositional plexus ratio in any of the oral bacterial flora.
単球細胞がヒト単球細胞である、請求項1記載の方法。 The method according to claim 1, wherein the monocyte cell is a human monocyte cell. ヒト単球細胞がTHP−1細胞である、請求項2記載の方法。 The method according to claim 2, wherein the human monocyte cell is a THP-1 cell. ・口腔細菌叢中のBacteroidetes門細菌の含有比率、
・口腔細菌叢中のProteobacteria門細菌の含有比率、または
・Bacteroidetes門細菌の含有比率のProteobacteria門細菌の含有比率に対する量比
のいずれかの口腔細菌叢中の構成叢比を予測するための、インターロイキン−10に対する抗体を含むインターロイキン−10量測定キット。
・ Content ratio of Bacteroidetes phylum bacteria in the oral flora,
-Content ratio of Proteobacteria phylum bacteria in the oral flora, or
-Amount ratio of the content ratio of Bacteroidetes phylum bacteria to the content ratio of Proteobacteria phylum bacteria
An interleukin-10 amount measurement kit containing an antibody against interleukin-10 for predicting the composition ratio in any of the oral bacterial flora.
口腔細菌叢中の構成叢比を、以下のいずれか: The composition ratio in the oral bacterial plexus is one of the following:
・培養液中のIL-10の測定値が30 pg/mL以上のとき、口腔細菌叢中のBacteroidetes門細菌含有比率が30%以上と予測するとの情報;-Information that when the measured value of IL-10 in the culture solution is 30 pg / mL or more, the content ratio of Bacteroidetes phylum bacteria in the oral flora is predicted to be 30% or more;
・培養液中のIL-10の測定値が30 pg/mL以上のとき、口腔細菌叢中のProteobacteria門細菌含有比率が20%未満と予測するとの情報;-Information that when the measured value of IL-10 in the culture solution is 30 pg / mL or more, the content ratio of Proteobacteria phylum bacteria in the oral flora is predicted to be less than 20%;
・培養液中のIL-10の測定値が85 pg/mL以上のとき、口腔細菌叢中のBacteroidets門細菌のProteobacteria門細菌に対する量比(Bacteroidetes門細菌の比率/Proteobacteria門細菌の比率)が1.7以上と予測するとの情報;-When the measured value of IL-10 in the culture medium is 85 pg / mL or more, the amount ratio of Bacteroidetes phylum bacteria to Proteobacteria phylum bacteria in the oral flora (ratio of Bacteroidetes phylum bacteria / ratio of Proteobacteria phylum bacteria) is 1.7. Information that is predicted to be above;
に基づいて予測する、請求項4に記載のインターロイキン−10量測定キット。The interleukin-10 quantity measurement kit according to claim 4, which is predicted based on the above.
JP2017181000A 2017-09-21 2017-09-21 How to predict the composition ratio in the oral bacterial flora Active JP6836756B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017181000A JP6836756B2 (en) 2017-09-21 2017-09-21 How to predict the composition ratio in the oral bacterial flora

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017181000A JP6836756B2 (en) 2017-09-21 2017-09-21 How to predict the composition ratio in the oral bacterial flora

Publications (2)

Publication Number Publication Date
JP2019054752A JP2019054752A (en) 2019-04-11
JP6836756B2 true JP6836756B2 (en) 2021-03-03

Family

ID=66105860

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017181000A Active JP6836756B2 (en) 2017-09-21 2017-09-21 How to predict the composition ratio in the oral bacterial flora

Country Status (1)

Country Link
JP (1) JP6836756B2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012524910A (en) * 2009-04-23 2012-10-18 カリフォルニア インスティチュート オブ テクノロジー Method and system for identifying immunomodulators
JP5863035B2 (en) * 2012-03-07 2016-02-16 国立大学法人 東京大学 Method for detecting inflammatory bowel disease and method for examining human salivary bacterial flora
DK3030247T3 (en) * 2013-08-09 2018-08-13 Ab Biotics Sa PROBIOTIC FOR EXCESSIVE BABY GRADE
JP6296747B2 (en) * 2013-10-17 2018-03-20 国立大学法人 岡山大学 Diagnosis of IgA nephropathy by examination of human salivary bacterial flora

Also Published As

Publication number Publication date
JP2019054752A (en) 2019-04-11

Similar Documents

Publication Publication Date Title
Petruccioli et al. Analytical evaluation of QuantiFERON-Plus and QuantiFERON-Gold In-tube assays in subjects with or without tuberculosis
Mentis et al. Epidemiology and Diagnosis of H elicobacter pylori infection
Bloos et al. Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study
Steigedal et al. Lipocalin 2 imparts selective pressure on bacterial growth in the bladder and is elevated in women with urinary tract infection
Duthie et al. A rapid ELISA for the diagnosis of MB leprosy based on complementary detection of antibodies against a novel protein-glycolipid conjugate
Saito et al. Impact of cytokine expression in the pre-implanted donor lung on the development of chronic lung allograft dysfunction subtypes
Jungersen et al. Use of the johnin PPD interferon-gamma assay in control of bovine paratuberculosis
Menard et al. Self-collected vaginal swabs for the quantitative real-time polymerase chain reaction assay of Atopobium vaginae and Gardnerella vaginalis and the diagnosis of bacterial vaginosis
US20150141279A1 (en) Method for Diagnosing Tuberculosis Disease by Detecting Induced Markers After Stimulation of T-Cells With Antigens
Awoniyi et al. Evaluation of cytokine responses against novel Mtb antigens as diagnostic markers for TB disease
JP5258584B2 (en) Clinical correlation
Verweij et al. Serovar D and E of serogroup B induce highest serological responses in urogenital Chlamydia trachomatis infections
Butt et al. Antibody responses to Streptococcus Gallolyticus subspecies Gallolyticus proteins in a large prospective colorectal cancer cohort consortium
US10725039B2 (en) Biomarker signatures for Lyme disease and methods of use thereof
Varshney et al. Association of Mycoplasma pneumoniae and asthma among Indian children
Suwarsa et al. Skin tissue expression and serum level of thymic stromal lymphopoietin in patients with psoriasis vulgaris
Hoel et al. IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting
AU2007297318A1 (en) Method and kit for detecting if an individual is susceptible to progress to an active mycobacterial disease
Hu et al. Analysis of the diagnostic efficacy of the QuantiFERON-TB Gold In-Tube assay for preoperative differential diagnosis of spinal tuberculosis
JP2017524943A (en) S. Predicting Aureus disease
Al-Timimi et al. HLA-DR/DQ genotypes in Kurd patients with rheumatoid arthritis: relation to disease activity
KR101317748B1 (en) Method for predicting iga nephropathy and method for screening iga nephropathy patient
JP6836756B2 (en) How to predict the composition ratio in the oral bacterial flora
Ruiz et al. Impact of severe lymphopenia on the early prediction of clinical outcome in hospitalized patients with pneumococcal community-acquired pneumonia
Lund et al. Reactive arthritis in relation to internal derangements of the temporomandibular joint: a case control study

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191007

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190926

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191024

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20191115

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200817

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201013

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210122

R150 Certificate of patent or registration of utility model

Ref document number: 6836756

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150